drugset
Drugs / selurampanel
last change Mar 2018 re-read 9 days ago

selurampanel

also known as BGG492

Small molecule

Developed for
focal epilepsy · epilepsy · migraine disorder · photosensitive epilepsy
Investigated by
Novartis · Novartis Pharmaceuticals

Trials 8

today NCT01649050 · Ph 2 NCT01617941 · Ph 2 NCT01338805 · Ph 2 NCT01167335 · Ph 2 NCT01147003 · Ph 2 NCT00892203 · Ph 2 NCT00887861 · Ph 2 NCT00784212 · Ph 2
2009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 28 trials · 1 missed
Phase 2 NCT01649050 Oct 2016 → Mar 2018 — Novartis Pharmaceuticals Withdrawn No outcome recorded
Phase 2 NCT01617941 May → Nov 2016 — Novartis Pharmaceuticals Withdrawn No outcome recorded
Phase 2 NCT01338805 Jun 2011 → Jul 2012 focal epilepsy Novartis Pharmaceuticals Completed No outcome recorded
Phase 2 NCT01167335 Aug → Nov 2010 focal epilepsy Novartis Withdrawn No outcome recorded
Phase 2 NCT01147003 Jun 2010 → Sep 2011 focal epilepsy Novartis Completed No outcome recorded
Phase 2 NCT00892203 Apr 2009 → Aug 2010 migraine disorder Novartis Completed Missed primary
Phase 2 NCT00887861 Mar 2009 → Aug 2010 epilepsy Novartis Completed No outcome recorded
Phase 2 NCT00784212 Oct 2008 → Sep 2010 photosensitive epilepsy Novartis Pharmaceuticals Completed No outcome recorded
Comparator or background therapy1 trial
Phase 2 NCT02150213 Background Aug 2014 → Sep 2015 adrenal cortex adenoma, uterine corpus endometrial stromal sarcoma Novartis Pharmaceuticals Completed No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 11 sources stand behind the page.

FieldValueCited text
Known as selurampanel “Examine the efficacy of a competitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)/kainate glutamate receptor antagonist, selurampanel (BGG492), in the human...” PMID 25963722 ↗ May 2015
Known as BGG492 ClinicalTrials.gov intervention name — accepted as the source's own label NCT01147003 ↗
8

NCT00784212 ↗

NCT01338805 ↗

NCT00887861 ↗

NCT01617941 ↗

NCT01649050 ↗

NCT02150213 ↗

NCT00892203 ↗

NCT01167335 ↗
Action Inhibit “competitive AMPA/kainate receptor antagonist” PMID 25963722 ↗ May 2015
Modality Small molecule — CHEMBL3545042 ↗
Route Oral “single oral BGG492 doses” PMID 25963722 ↗ May 2015